Home    Back

Ionis-fb-lrx    (DrugBank: -)

1 disease
IDDisease name (Link within this page)Number of trials
66IgA nephropathy1

66. IgA nephropathy    [ 199 clinical trials,   214 drugs,   (DrugBank: 57 drugs),   32 drug target genes,   128 drug target pathways]
Searched query = "IgA nephropathy", "IgA nephritis", "Berger disease", "IgA-IgG nephropathy"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 199 trial found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1NCT04014335
(ClinicalTrials.gov)		December 4, 20198/7/2019A Study to Evaluate the Effectiveness and Safety of IONIS-FB-LRx, an Antisense Inhibitor of Complement Factor B, in Adult Participants With Primary IgA NephropathyAn Open-Label Phase 2a Clinical Study to Evaluate the Effectiveness and Safety of IONIS-FB-LRx, an Antisense Inhibitor of Complement Factor B, in Adult Subjects With Primary IgA NephropathyPrimary IgA NephropathyDrug: IONIS-FB-LRxIonis Pharmaceuticals, Inc.NULLRecruiting18 Years75 YearsAll10Phase 2Australia;Canada;New Zealand